PP_1170x120_10-25-21

RRMS

Pfizer to buy U.S. rights for potential MS generic drug

Pfizer to buy U.S. rights for potential MS generic drug

NEW YORK — Pfizer Inc. has entered into an agreement with Synthon to acquire the exclusive U.S. commercialization rights for glatiramer acetate, a potential generic version of Teva Pharmaceuticals’ Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS). Pfizer said Monday that under the agreement, it will have exclusive rights to commercialize both dosage